• Lexeo Therapeutics won FDA RMAT designation for LX2020, an AAV gene therapy for PKP2-associated arrhythmogenic cardiomyopathy.
• Designation was supported by interim data from the ongoing Phase I/II HEROIC-PKP2 trial.
• LX2020 also holds FDA Orphan Drug, Fast Track designations, supporting an expedited development path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.